The United States Department of Defense has granted USD71m to INOVIO (NASDAQ:INO), a United States-based biotechnology company, in order to support the mass production of the firm's CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices that are used to deliver INO-4800 directly into the skin, it was reported on Tuesday.
INO-4800 is INOVIO's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. CELLECTRA 3PSP is a device that runs on 'AA' batteries and can be stockpiled in large quantities without maintenance. The device is produced at the company's San Diego device manufacturing facility and it has produced initial quantities of the device.
The company is to reveal interim results of United States Phase one clinical studies of INO-4800 later this month. It is planning a Phase two/three efficacy trial this summer.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project